ワカバヤシ ヒデタカ
Wakabayashi Hidetaka
若林 秀隆 所属 医学部 医学科(東京女子医科大学病院) 職種 教授・基幹分野長 |
|
論文種別 | 総説 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Rehabilitation pharmacotherapy: A scoping review. |
掲載誌名 | 正式名:Geriatrics & gerontology international 略 称:Geriatr Gerontol Int ISSNコード:14470594/14470594 |
掲載区分 | 国外 |
巻・号・頁 | 20(7),pp.655-663 |
著者・共著者 | Kose Eiji, Wakabayashi Hidetaka |
担当区分 | 2nd著者 |
発行年月 | 2020/07 |
概要 | Many patients in rehabilitation facilities are affected by polypharmacy. Polypharmacy is associated with rehabilitation outcomes and functional recovery. Consequently, a combination of rehabilitation and pharmacotherapy may improve the outcomes of older people undergoing rehabilitation. A recent report described the concept of rehabilitation pharmacotherapy. The concept envisages helping frail older people and people with disabilities to achieve the highest possible body function, activity level and quality of life. There are two key tenets of rehabilitation pharmacotherapy: "pharmacotherapy in consideration of rehabilitation" and "rehabilitation in consideration of pharmacotherapy." "Pharmacotherapy in consideration of rehabilitation" includes use of drugs to treat impairment, activity limitation and participation restriction based on the International Classification of Functioning, Disability, and Health. "Rehabilitation in consideration of pharmacotherapy" refers to tailoring of rehabilitation considering the content of pharmacotherapy. With respect to drugs and motor dysfunction, anticholinergic drugs are associated with dysphagia and fractures. Increased use of potentially inappropriate medications may adversely affect the nutritional status. With respect to activities of daily living, polypharmacy and use of potentially inappropriate medications negatively affect the improvement in motor function during rehabilitation. Potent anticholinergic drugs are more likely to impede the improvement in cognitive function. In this review, we address the concept of rehabilitation pharmacotherapy and discuss its importance from the perspective of polypharmacy, the effect of drugs on disability and disease, nutritional status and activities of daily living. Geriatr Gerontol Int 2020; 20: -. |
DOI | 10.1111/ggi.13975 |
PMID | 32691925 |